See analyst estimates and all valuation multiples for Biopharmaceuticals
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$747B | 14.1x | 35.0x | |
$405B | 6.9x | 15.3x | |
$391B | 4.3x | 11.9x | |
$320B | 6.5x | 13.0x | |
$283B | 3.6x | 9.2x | |
$263B | 4.7x | 11.5x | |
$247B | 4.2x | 12.2x | |
$235B | 3.6x | 8.4x | |
$207B | 6.0x | 11.1x | |
$190B | 3.0x | 7.8x | |
$153B | 5.3x | 12.1x | |
$135B | 2.9x | 10.6x | |
$134B | 2.5x | 8.5x | |
$116B | 10.1x | 35.2x | |
$96.7B | 2.2x | 6.5x | |
$86.9B | 5.6x | 16.7x | |
$76.3B | 2.4x | 9.3x | |
$74.0B | 7.9x | 18.3x | |
$71.3B | 8.6x | 17.3x | |
$70.1B | 1.3x | 6.1x | |
$66.1B | 2.6x | 9.2x | |
$54.1B | 6.0x | 21.1x | |
$49.7B | 11.8x | 43.9x | |
$44.1B | 7.0x | 24.7x | |
$37.7B | 2.8x | 13.6x | |
$34.0B | 1.9x | 6.7x | |
$30.6B | 10.5x | 33.9x | |
$27.9B | 2.5x | 12.1x | |
$24.2B | 1.7x | 5.6x | |
$23.7B | 2.5x | 7.4x | |
$23.2B | 1.4x | 6.3x | |
$22.9B | 2.3x | 6.5x | |
$21.7B | 1.6x | 8.6x | |
$20.9B | 7.2x | 7.8x | |
$20.6B | 11.5x | 30.8x | |
$19.1B | 2.2x | 8.9x | |
$16.9B | 134.5x | 317.4x | |
$16.8B | 11.3x | 265.3x | |
$15.6B | 29.1x | 67.2x | |
$15.6B | 5.3x | 14.3x | |
$13.4B | 9.6x | 29.5x | |
$13.1B | 8.7x | 34.2x | |
$12.8B | 3.0x | 13.2x | |
$12.8B | 3.9x | 15.3x | |
$12.7B | 5.0x | 21.0x | |
$12.5B | 30.8x | -2373.3x | |
$12.1B | 2.1x | 14.9x | |
$12.1B | 3.1x | 11.7x | |
$11.6B | 4.1x | 11.2x | |
$11.6B | 2.0x | 12.4x | |
$11.1B | 5.9x | 18.5x | |
$11.0B | 1.7x | 5.6x | |
$10.9B | 3.9x | 13.5x | |
$10.5B | 2.6x | 10.4x | |
$10.3B | 3.3x | 8.1x | |
$10.3B | 2.9x | 8.3x | |
$10.2B | 3.7x | 15.6x | |
$10.0B | 2.4x | 6.7x | |
$9.7B | 35.4x | -220.3x | |
$9.7B | 1.6x | 12.5x | |
$9.4B | 2.9x | 7.3x | |
$8.2B | 10.8x | 39.9x | |
$7.8B | 6.9x | 10.8x | |
$7.6B | 0.2x | 3.5x | |
$7.6B | 2.0x | 9.6x | |
$7.5B | 2.2x | 9.6x | |
$7.4B | 4.0x | 18.9x | |
$7.3B | 4.5x | 25.0x | |
$7.3B | n/a | n/a | |
$7.3B | 1.3x | 10.8x | |
$7.2B | 4.3x | 8.9x | |
$7.2B | n/a | n/a | |
$7.0B | 2.1x | 7.9x | |
$6.7B | 15.1x | 20.7x | |
$6.5B | 9.6x | 33.7x | |
$6.5B | n/a | n/a | |
$6.5B | 1.5x | 8.1x | |
$6.3B | 4.1x | 20.9x | |
$6.3B | 2.7x | 10.0x | |
$6.1B | 13.6x | 43.1x | |
$6.1B | 3.9x | 56.6x | |
$5.9B | 5.0x | 16.3x | |
$5.4B | n/a | n/a | |
$5.4B | 12.1x | 38.8x | |
$5.3B | 6.6x | 22.8x | |
$5.2B | 2.7x | 11.0x | |
$5.2B | 17.9x | -47.4x | |
$5.1B | 1.8x | 7.9x | |
$5.1B | 5.7x | 13.3x | |
$5.0B | 1.9x | 5.0x | |
$4.9B | 12.9x | 76.5x | |
$4.8B | 1.4x | 6.3x | |
$4.7B | 14.6x | -49.1x | |
$4.6B | 1.9x | 8.1x | |
$4.5B | 3.1x | 11.4x | |
$4.4B | 9.5x | 21.8x | |
$4.4B | 8.4x | 29.8x | |
$4.4B | 2.1x | 13.9x | |
$4.3B | 44.2x | -5871.6x | |
$4.2B | 10.7x | 28.4x | |
$4.2B | 2.9x | 11.1x | |
$4.0B | 4.8x | 21.2x | |
$3.8B | 6.6x | 21.2x | |
$3.8B | 4.7x | 20.3x | |
$3.7B | 5.7x | 14.3x | |
$3.7B | n/a | n/a | |
$3.6B | 2.1x | 10.4x | |
$3.5B | n/a | n/a | |
$3.5B | n/a | n/a | |
$3.5B | n/a | n/a | |
$3.4B | 33.4x | -43.8x | |
$3.4B | 3.9x | 14.9x | |
$3.4B | 4.7x | 16.0x | |
$3.3B | 18.7x | -60.0x | |
$3.3B | 855.3x | -11.5x | |
$3.2B | 8.5x | 25.2x | |
$3.2B | 2.3x | 8.5x | |
$3.2B | n/a | n/a | |
$3.1B | n/a | n/a | |
$2.8B | 2.5x | 12.0x | |
$2.7B | 2.2x | 10.9x | |
$2.7B | 16.8x | -36.8x | |
$2.6B | 3.3x | 18.3x | |
$2.5B | 4.0x | 14.1x | |
$2.4B | 8.0x | 15.7x | |
$2.4B | 35.6x | -1210.3x | |
$2.4B | 3.2x | 19.6x | |
$2.4B | 6.1x | 14.0x | |
$2.3B | 5.6x | 15.6x | |
$2.2B | 3.2x | 7.6x | |
$2.2B | 14.6x | 34.3x | |
$2.0B | 3.0x | -87.9x | |
$2.0B | 26.5x | -26.3x | |
$1.9B | 4.8x | 13.7x | |
$1.9B | 1.7x | 6.7x | |
$1.9B | n/a | n/a | |
$1.9B | 2.7x | 10.5x | |
$1.8B | 4.4x | 17.1x | |
$1.8B | 3.5x | 158.0x | |
$1.7B | 6.6x | -18.2x | |
$1.7B | 2.4x | 4.0x | |
$1.6B | 4.1x | n/a | |
$1.6B | 0.7x | 4.4x | |
$1.6B | 15.4x | 31.9x | |
$1.6B | 50.3x | n/a | |
$1.6B | 2.6x | 10.9x | |
$1.6B | 13.6x | -31.6x | |
$1.5B | 4.9x | -10.9x | |
$1.5B | 7.1x | 28.7x | |
$1.5B | n/a | n/a | |
$1.4B | 5.9x | 24.9x | |
$1.4B | 2.0x | 5.3x | |
$1.4B | 2.2x | 8.3x | |
$1.4B | n/a | -6.3x | |
$1.4B | 10.1x | n/a | |
$1.3B | 76.0x | -14.5x | |
$1.3B | 1.3x | 5.5x | |
$1.3B | 4.4x | -16.1x | |
$1.3B | n/a | -8.0x | |
$1.3B | n/a | n/a | |
$1.3B | 0.6x | 5.2x | |
$1.2B | 3.3x | n/a | |
$1.2B | 2.9x | 14.1x | |
$1.2B | 10.5x | 44.4x | |
$1.1B | 2.4x | 15.9x | |
$1.1B | 1.7x | -9.5x | |
$1.1B | 22.4x | n/a | |
$1.1B | 5.9x | 22.3x | |
$1.1B | n/a | -6.1x | |
$1.1B | 4.7x | 10.8x | |
$1.1B | n/a | n/a | |
$1.1B | 11.0x | 17.9x | |
$1.0B | 271260.0x | -8.5x | |
$1.0B | 4.4x | 54.9x | |
$1.0B | 2.9x | -52.4x | |
$1.0B | n/a | -2.8x | |
$1.0B | n/a | n/a | |
$996M | n/a | n/a | |
$979M | 9.1x | 266.2x | |
$978M | 12.0x | -6.4x | |
$973M | 5.3x | n/a | |
$954M | 3.8x | n/a | |
$929M | n/a | -4.3x | |
$924M | 9.1x | 37.8x | |
$923M | 3.7x | 4.6x | |
$916M | 1.0x | 5.6x | |
$895M | 2.9x | 26.7x | |
$868M | 4.0x | 60.8x | |
$866M | 1.3x | 6.9x | |
$833M | n/a | n/a | |
$803M | 4.3x | 20.2x | |
$793M | 14835.8x | -3.7x | |
$784M | 186.2x | -11.3x | |
$775M | n/a | n/a | |
$772M | n/a | n/a | |
$768M | 36.4x | -226.7x | |
$752M | 7.9x | -6.5x | |
$745M | n/a | -5.4x | |
$734M | n/a | n/a | |
$733M | 2.7x | 11.4x | |
$718M | n/a | n/a | |
$708M | n/a | n/a | |
$708M | 2.2x | 853.1x | |
$703M | 158.3x | -3.0x | |
$694M | 784.0x | -7.3x | |
$681M | n/a | n/a | |
$661M | 5.7x | 21.5x | |
$641M | n/a | -7.2x | |
$632M | 5.7x | -3.1x | |
$618M | n/a | -6.5x | |
$612M | 2.0x | 6.0x | |
$601M | n/a | -3.4x | |
$594M | 1.3x | 6.3x | |
$586M | 8.1x | -28.6x | |
$586M | 5.4x | -5.3x | |
$565M | n/a | n/a | |
$552M | n/a | n/a | |
$526M | 7.4x | 26.4x | |
$519M | 138.8x | -13.7x | |
$519M | 26.9x | -2.8x | |
$509M | n/a | n/a | |
$508M | 5.0x | 14.7x | |
$496M | 84.4x | n/a | |
$492M | 355.8x | -23.9x | |
$491M | n/a | n/a | |
$488M | 1.3x | 10.0x | |
$463M | 13.2x | n/a | |
$446M | 1.3x | 5.5x | |
$433M | 3.6x | -88.4x | |
$427M | 2.7x | 12.0x | |
$425M | 18.8x | 94.6x | |
$421M | n/a | n/a | |
$419M | 1.2x | 12.9x | |
$419M | n/a | -3.7x | |
$409M | n/a | -3.1x | |
$404M | 22.3x | -3.6x | |
$399M | n/a | n/a | |
$391M | 4.9x | -7.5x | |
$383M | 78.1x | n/a | |
$382M | 2.2x | 9.7x | |
$356M | 1.3x | 8.8x | |
$338M | 0.8x | 7.3x | |
$336M | 4.9x | 30.2x | |
$322M | 2.5x | 5.2x | |
$316M | n/a | n/a | |
$311M | 4.0x | -0.9x | |
$308M | 12.2x | -5.6x | |
$307M | 5.2x | n/a | |
$303M | n/a | n/a | |
$303M | 7.1x | 31.7x | |
$299M | n/a | n/a | |
$299M | 13.0x | -1.9x | |
$298M | 27.0x | n/a | |
$293M | 2.6x | -6.9x | |
$287M | n/a | n/a | |
$284M | n/a | n/a | |
$270M | n/a | n/a | |
$265M | n/a | n/a | |
$260M | 6.7x | -21.6x | |
$255M | n/a | -2.3x | |
$249M | 1.2x | -3.7x | |
$242M | 5.0x | 17.5x | |
$233M | n/a | -2.0x | |
$227M | 9.3x | -5.1x | |
$227M | 2.1x | -1.2x | |
$224M | 9.6x | 13.7x | |
$221M | n/a | n/a | |
$219M | 3.1x | n/a | |
$218M | 1.5x | -1.1x | |
$218M | 3.3x | 6.7x | |
$213M | 59.7x | n/a | |
$212M | 2.9x | -2.9x | |
$203M | 38.0x | -4.5x | |
$199M | 1.7x | -2.1x | |
$198M | 5.7x | -0.9x | |
$198M | n/a | -12.9x | |
$197M | 2.9x | -8.3x | |
$195M | n/a | n/a | |
$195M | n/a | -2.2x | |
$193M | n/a | n/a | |
$188M | n/a | n/a | |
$188M | 95.3x | -1.6x | |
$188M | 14431.5x | -1.8x | |
$186M | 13.8x | -0.6x | |
$183M | 1.4x | 13.7x | |
$174M | 28.2x | -3.4x | |
$169M | 2.7x | -0.5x | |
$168M | 33.3x | -5.0x | |
$167M | 1.5x | 5.7x | |
$165M | n/a | -1.2x | |
$159M | 21.9x | -5.7x | |
$157M | 12.5x | -5.8x | |
$157M | n/a | -0.9x | |
$157M | 16.9x | -0.9x | |
$152M | 43.9x | -0.7x | |
$138M | 1.6x | -3.5x | |
$137M | n/a | n/a | |
$133M | n/a | n/a | |
$128M | n/a | n/a | |
$126M | 28.3x | -3.2x | |
$126M | 2282.1x | -8.3x | |
$123M | 5.8x | 16.6x | |
$115M | 4.3x | -1.2x | |
$114M | n/a | n/a | |
$113M | n/a | -3.1x | |
$112M | 1.8x | 11.0x | |
$110M | 1.8x | 32.6x | |
$109M | n/a | -7.5x | |
$104M | 2.8x | -6.6x | |
$104M | n/a | n/a | |
$94.9M | n/a | -0.9x | |
$91.8M | n/a | n/a | |
$90.2M | 3.4x | -1.6x | |
$88.8M | n/a | n/a | |
$88.6M | 2.9x | 12.1x | |
$85.8M | 1.8x | n/a | |
$83.1M | 13.8x | -2.5x | |
$82.7M | 1.4x | n/a | |
$81.9M | 9.2x | -3.4x | |
$81.7M | n/a | n/a | |
$81.2M | n/a | n/a | |
$80.2M | 2.5x | -0.6x | |
$77.7M | n/a | n/a | |
$76.7M | 0.4x | -1.1x | |
$71.0M | 11.5x | 14.1x | |
$69.1M | 14.5x | n/a | |
$68.7M | n/a | n/a | |
$68.6M | n/a | n/a | |
$68.1M | n/a | -0.5x | |
$63.6M | n/a | -0.6x | |
$59.7M | 17.7x | -7.3x | |
$58.0M | n/a | n/a | |
$50.9M | 0.3x | -0.1x | |
$49.9M | 1.2x | 6.4x | |
$49.6M | 96.6x | -6.8x | |
$48.4M | 8.7x | -4.3x | |
$47.7M | n/a | -0.2x | |
$47.3M | n/a | n/a | |
$42.2M | 7.5x | -4.7x | |
$41.5M | n/a | n/a | |
$40.6M | n/a | n/a | |
$39.6M | n/a | n/a | |
$39.3M | 8.3x | -15.5x | |
$38.4M | 3.0x | -13.2x | |
$38.4M | 103.1x | -3.5x | |
$37.6M | n/a | -3.1x | |
$37.3M | n/a | n/a | |
$36.7M | 6.3x | n/a | |
$36.1M | 1.4x | 7.9x | |
$34.0M | n/a | -1.6x | |
$33.9M | 18.0x | -86.3x | |
$33.7M | n/a | n/a | |
$33.3M | 360.5x | n/a | |
$33.3M | 63.6x | -4.2x | |
$32.4M | n/a | n/a | |
$32.0M | n/a | n/a | |
$31.9M | n/a | n/a | |
$31.1M | n/a | n/a | |
$29.3M | n/a | -5.0x | |
$28.5M | 25.4x | -395.4x | |
$27.8M | n/a | -9.2x | |
$27.5M | 7.1x | n/a | |
$26.6M | 61.7x | n/a | |
$26.1M | 127.0x | -4.0x | |
$26.0M | n/a | n/a | |
$24.4M | n/a | -7.3x | |
$24.1M | n/a | n/a | |
$21.9M | 6.4x | n/a | |
$21.7M | 3.5x | -1.3x | |
$21.6M | n/a | -13.1x | |
$21.4M | n/a | n/a | |
$21.2M | n/a | n/a | |
$21.0M | 3.8x | -1.3x | |
$20.8M | n/a | n/a | |
$20.5M | 7.0x | -1.3x | |
$19.2M | n/a | n/a | |
$18.4M | n/a | n/a | |
$17.4M | 40.7x | -1.7x | |
$17.4M | n/a | n/a | |
$17.2M | n/a | n/a | |
$17.1M | n/a | n/a | |
$16.8M | 8.0x | -22.4x | |
$16.4M | 2.5x | 7.7x | |
$16.4M | n/a | n/a | |
$16.0M | 12.1x | -7.3x | |
$15.9M | n/a | n/a | |
$15.5M | n/a | n/a | |
$14.8M | n/a | n/a | |
$14.5M | 41.1x | -7.5x | |
$14.0M | n/a | -5.6x | |
$13.6M | n/a | n/a | |
$13.3M | n/a | n/a | |
$13.2M | n/a | n/a | |
$12.8M | n/a | n/a | |
$12.6M | n/a | n/a | |
$12.6M | 2.0x | -6.5x | |
$12.2M | n/a | n/a | |
$11.5M | n/a | n/a | |
$10.9M | n/a | n/a | |
$10.5M | 12.0x | n/a | |
$10.5M | n/a | n/a | |
$10.3M | n/a | n/a | |
$10.0M | n/a | -5.0x | |
$9.4M | 4.0x | -0.4x | |
$9.2M | n/a | n/a | |
$9.0M | 6.7x | -2.1x | |
$8.9M | n/a | n/a | |
$8.9M | n/a | n/a | |
$8.6M | 41.0x | -2.6x | |
$8.5M | 2.7x | -2.5x | |
$8.5M | n/a | n/a | |
$8.3M | 49.4x | -8.0x | |
$7.8M | n/a | -2.4x | |
$7.2M | n/a | n/a | |
$6.9M | n/a | n/a | |
$6.8M | n/a | n/a | |
$6.6M | n/a | n/a | |
$6.6M | n/a | -1.4x | |
$6.4M | 5.2x | n/a | |
$6.0M | n/a | n/a | |
$5.7M | n/a | n/a | |
$5.3M | n/a | n/a | |
$5.2M | n/a | n/a | |
$5.0M | n/a | n/a | |
$4.9M | n/a | -1.3x | |
$4.6M | n/a | -2.1x | |
$4.1M | 0.3x | -0.3x | |
$3.9M | n/a | n/a | |
$3.7M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.4M | n/a | n/a | |
$3.4M | n/a | n/a | |
$3.3M | 5.5x | -1.6x | |
$3.0M | 3.7x | -0.2x | |
$2.7M | n/a | n/a | |
$2.5M | n/a | n/a | |
$2.3M | n/a | n/a | |
$2.3M | n/a | n/a | |
$2.1M | 3.8x | -0.7x | |
$1.8M | n/a | n/a | |
$1.8M | n/a | 7.5x | |
$1.8M | 2.0x | n/a | |
$1.7M | 0.2x | -1.1x | |
$1.7M | n/a | n/a | |
$1.6M | n/a | n/a | |
$1.1M | n/a | n/a | |
$0.9M | n/a | n/a | |
$0.6M | n/a | n/a | |
$0.6M | n/a | n/a | |
$0.5M | n/a | n/a | |
$0.4M | n/a | n/a | |
$0.2M | n/a | n/a | |
$0.1M | n/a | n/a | |
-$1.1M | n/a | n/a | |
-$1.9M | n/a | n/a | |
-$5.0M | n/a | n/a | |
-$5.8M | n/a | n/a | |
-$6.2M | n/a | n/a | |
-$9.0M | -371.9x | 0.7x | |
-$11.2M | -7.5x | 0.2x | |
-$14.2M | n/a | n/a | |
-$18.2M | n/a | n/a | |
-$22.7M | n/a | n/a | |
-$24.5M | n/a | n/a | |
-$26.3M | -4.2x | 0.2x | |
-$27.9M | -8.3x | 0.4x | |
-$46.0M | -4.1x | 0.1x | |
-$46.9M | -6.7x | n/a | |
-$46.9M | -9.6x | 1.1x | |
-$63.2M | -0.8x | n/a | |
-$73.4M | n/a | 0.5x | |
-$74.9M | n/a | n/a | |
-$83.3M | -31.2x | 1.3x | |
-$99.3M | -42.9x | 0.5x | |
-$147M | -187.7x | 1.9x | |
-$153M | -2.9x | 0.8x | |
-$159M | -104.1x | 0.9x | |
-$1.8B | -5.6x | 10.3x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals